Widening the door: The evolution of hepatitis C treatment in patients with psychiatric disorders†‡
See Article on Page 991.
Potential conflict of interest: Dr. Arora is on the speaker's bureau of and received grants from Roche Pharmaceuticals and Schering-Pharmaceuticals. He also received grants from Vertex Pharmaceuticals and Valeant Pharmaceuticals.
No abstract is available for this article.